The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Open accessAbstract
Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). Materials and methods In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. Significance The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Density-functional thermochemistry. III. The role of exact exchange
Becke, A. D. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464913 · Cited by 103,767
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR
Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R., & Thornton, J. (1996) · Journal of Biomolecular NMR · doi:10.1007/bf00228148 · Cited by 5,502
SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T. G., Bertoni, M., Bordoli, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku340 · Cited by 4,632
MolProbity: More and better reference data for improved all‐atom structure validation
Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., et al. (2018) · Protein Science · doi:10.1002/pro.3330 · Cited by 4,599
Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
Stewart, J. J. P. (2007) · Journal of Molecular Modeling · doi:10.1007/s00894-007-0233-4 · Cited by 3,619
Cited by
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA
Adasme, M. F., Linnemann, K. L., Bolz, S. N., Kaiser, F., Salentin, S., Haupt, V. J., & Schroeder, M. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab294 · Cited by 1,999
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
COVID-19: Transmission, prevention, and potential therapeutic opportunities
Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.044 · Cited by 1,016
The epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Cardiovascular complications in COVID-19
Long, B., Brady, W. J., Koyfman, A., & Gottlieb, M. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.04.048 · Cited by 974
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923
Self-citationCOVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Assessment and characterisation of post‐COVID‐19 manifestations
Kamal, M., Abo Omirah, M., Hussein, A., & Saeed, H. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13746 · Cited by 603
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
Boettler, T., Newsome, P. N., Mondelli, M. U., Maticic, M., Cordero, E., Cornberg, M., & Berg, T. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100113 · Cited by 477
Jothimani, D., Venugopal, R., Abedin, M. F., Kaliamoorthy, I., & Rela, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.006 · Cited by 469
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Shah, B., Modi, P., & Sagar, S. R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117652 · Cited by 401
Abd El-Aziz, T. M., & Stockand, J. D. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104327 · Cited by 363
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
McCreary, E. K., & Pogue, J. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa105 · Cited by 334
del Amo, J., Polo, R., Moreno, S., Díaz, A., Martínez, E., Arribas, J. R., Jarrín, I., & Hernán, M. A. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3689 · Cited by 324
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Gasmi, A., Noor, S., Tippairote, T., Dadar, M., Menzel, A., & Bjørklund, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108409 · Cited by 305
RajÄáni, J. (2021) · Microbiology & Infectious Diseases · doi:10.33425/2639-9458.1120 · Cited by 303
Ghahremanian, S., Rashidi, M. M., Raeisi, K., & Toghraie, D. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.118901 · Cited by 299
SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
Elfiky, A. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1761882 · Cited by 284
Self-citationCurrent epidemiological and clinical features of COVID-19; a global perspective from China
Tu, H., Tu, S., Gao, S., Shao, A., & Sheng, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.011 · Cited by 283
Paital, B., Das, K., & Parida, S. K. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138914 · Cited by 281
Sharma, J., Kumar Bhardwaj, V., Singh, R., Rajendran, V., Purohit, R., & Kumar, S. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2020.128933 · Cited by 255
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
Metadata
- Authors
- Elfiky, A. A.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 248
- Pages
- 117477
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3007227604
- Cited by
- 715
- References
- 43
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.